For example, if diagnosed with MDS, patients carrying isolated UBA1 mutations classify as low-risk MDS, for which erythroid stimulating agents (ESA) and luspatercept, an erythroid maturation agent, may be used to manage anemia [28]. The gene discussed is UBA1; the disease is myelodysplastic syndrome.